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license (http://creativecommons.org/Abstract Mitral valve prolapse (MVP) results from the systolic movement of a portion(s) or
segment(s) of the mitral valve leaflet(s) into the left atrium during left ventricular (LV) systole.
It should be emphasised that MVP alone, as defined by imaging techniques, may comprise a
non-specific finding because it also depends on the LV volume, myocardial contractility and
other LV hemodynamics. Thus, a floppy mitral valve (FMV) should be the basis for the diagnosis
of MVP. Two types of symptoms may be defined in these patients. In one group, symptoms are
directly related to progressive mitral regurgitation and its complications. In the other group,
symptoms cannot be explained only by the degree of mitral regurgitation alone; neuroendo-
crine dysfunction has been implicated for the explanation of symptoms in this group of pa-
tients that today is referred as the FMV/MVP syndrome. When significant mitral
regurgitation is present in a patient with FMV/MVP, surgical intervention is recommended. In
patients with a prohibitive risk for surgery, transcatheter mitral valve repair using a mitraclip
device may be considered. Furthermore, transcatheter mitral valve replacement may repre-
sent an option in the near future as clinical trials are underway. In this brief review, the cur-
rent concepts related to FMV/MVP and FMV/MVP syndrome will be discussed.
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Few diseases have evoked more interest and controversy
during the previous century than floppy mitral valve (FMV)/
mitral valve prolapse (MVP). These controversies are
related, at least in part, to the following four reasons.1,2
1. There is a lack of a precise definition for FMV/MVP.
MVP occurs when one, both, or a portion of the mitral valve
leaflets extend above the plane of the atrioventricular
junction during left ventricular (LV) systole.1e6 However, it
should be noted that MVP may be a non-specific finding
because it also depends on LV haemodynamics, such as
myocardial contractility, LV volume, and heart rate.3,6
Furthermore, the evolution of technology over the years
has resulted in various definitions of MVP. For a long period
of time, MVP was the central or only issue, and the diag-
nosis of MVP was completely dissociated from the FMV
morphology.3,6 However, to date, it is apparent that FMV is
the central issue in the MVP - mitral valvular regurgitation
story. The term FMV originates from surgical and patho-
logical studies and refers to the expansion of the area of
the mitral valve leaflets with elongated chordae tendineae,
chordae tendineae rupture, and mitral annular dilatation.
Thus, rather than asking the question does this individual
have MVP, the question should be does this individual have
FMV2,3,6?
2. The natural history of FMV/MVP and the occurrence of
mitral regurgitation requires long-term follow-up with
several evaluations to understand the life history of the
disease. The follow-up of an uncomplicated course during a
relative short period of time has resulted in the miscon-
ception that FMV/MVP is benign.2,7,8
3. A subgroup of patients with FMV/MVP may have
symptoms that are not directly related to the severity of
mitral regurgitation, but rather neurohumoral activation
and other abnormalities (subsequently discussed); these
patients today are referred to as having the FMV/MVP
syndrome. The lack of an association between the severity
of mitral regurgitation and symptoms was also a cause of
confusion for a long period of time.1,3,8
4. FMV/MVP may be a part of a well-recognised syndrome
of heritable connective tissue disorders, such as Marfan
syndrome, Ehlers-Danlos syndrome, and adult polycystic
kidney disease.9e12 The fact that clinicians were often not
able to separate isolated FMV/MVP from FMV/MVP that was a
component of a systemic heritable connective tissue disor-
der was also a cause of confusion. Furthermore, FMV/MVP
often shares several manifestations of Marfan syndrome,
including long limbs, thoracic cage deformities, striae atro-
phicae, and, in some cases, mild dilatation of the aorta or
abnormal aortic function. The acronym MASS (mitral, aorta,
skeleton, skin) was introduced to emphasise the involve-
ment of the mitral valve, aorta, skeleton and skin.12 Thus,
the clinical phenotype of FMV/MVP represents a heteroge-
neous group of patients with mitral valve or other abnor-
malities from mild to severe and constitutes a continuum
from Marfan syndrome at one extreme to isolated FMV/MVP
at the other extreme. To date, isolated FMV/MVP is consid-
ered a cardiovascular abnormality with a connective tissue
origin, which, in most instances does not fit the presently
recognised heritable connective tissue disorders.2,9,12 Byvirtue of its high frequency in the general population, FMV/
MVP comprises a larger group of patients with a connective
tissue abnormality of the heart. In this brief review, the
current concepts related to FMV/MVP and FMV/MVP syn-
drome will be discussed.
2. Inheritance
From a genetic perspective, FMV/MVP is a heterogeneous
group.2,3,13e17 To date, at least two forms of inheritance
exist. FMV/MVP may be transmitted by an autosomal
dominant form (most common) with a variable degree of
penetration. Another less common form is transmitted
through the X-chromosome (chromosome Xq28).16 For
autosomal dominant transmission, three gene loci have
been reported: chromosome 16 (16p12.1-p11.2); chromo-
some 11 (11p15.4); and chromosome 13 (13p31.3-p32.1).15
The elucidation of the genetic details in the near future
will enable a better classification of this common valvular
abnormality and will result in novel diagnostic pathways.
3. Pathology - Histopathology
1. Pathology. Surgically excised mitral valves from patients
with FMV/MVP and significant mitral valvular regurgitation
have a substantial surface area on both leaflets (18e25,
Fig. 1). The typical 2:1 ratio of the anterior to posterior
leaflet surface area is altered because of the enlargement
of all portions of the posterior leaflet. The mitral annular
size is also increased, and the chordae tendineae are
frequently thin, elongated or ruptured.18e20 Pathologic
studies have suggested that prolapse is limited to the pos-
terior leaflet in 67% of cases, the anterior leaflet in 10% of
cases, and both leaflets in 23% of cases.20 In a recent study
of 98 patients with FMV/MVP who had reconstructive mitral
valve surgery for severe mitral regurgitation, prolapse of
the posterior leaflet was identified in 53 patients, the
anterior leaflet in 4 patients, and both leaflets in 41 pa-
tients.26 Mitral valves with diffused thickening are currently
referred to as Barlow’s valves, whereas regional thickening
of the mitral valve leaflets are referred to as fibroelastic
deficiency valves. To date, it is not clear whether these two
entities are genetically different or represent a different
spectrum of abnormalities of the same disease (or both).
For this reason and to avoid further confusion, we believe
that it is better to define patients with FMV/MVP as having
diffuse or regional thickening of the mitral valve leaflets.3
2. Histology. The gross pathologic changes occur in the
presence of histological evidence of myxomatous degen-
eration, collagen disruption and dissolution, mucopolysac-
charide infiltration, and elastin fragmentation.18e24 The
most specific fundamental and characteristic changes
appear to comprise collagen dissolution and disruption in
the pars fibrosa of the mitral valve leaflets, which is
accompanied by proteoglycan accumulation. Similar histo-
logical abnormalities have also been demonstrated in the
chordae tendineae.24 Continuous pressure and stress during
LV systole on the mitral valve leaflets and chordae tendi-
neae contribute to the gradual progression of these histo-
logical abnormalities. In some cases, similar histological
Figure 2 Left panel: Mitral valve from a patient with floppy
mitral valve/mitral valve prolapse (FMV/MVP) and severe
mitral regurgitation; scanning electron microphotograph
(original magnification 400 X) indicates an irregular surface
with deep infolding. Right panel: Normal mitral valve; scanning
photomicrograph (original magnification 280 X) indicates a
smooth valve cusp surface covered by endothelial cells (from
ref 18).
Figure 1 Left upper and lower panels: Normal mitral valve. Right upper and lower panels: Floppy mitral valve. A Z anterior,
ALZ anterior leaflet, FMV/MVPZ floppy mitral valve/mitral valve prolapse, LAZ left atrium, LVZ left ventricle, PLZ posterior
leaflet (modified from ref 27).
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aortic valves that are associated with tricuspid or aortic
valve prolapse, respectively, and valvular regurgitation.2,3
The precise incidence of tricuspid or aortic valve abnor-
malities in patients with FMV/MVP remains elusive.
3. Scanning electron photomicrograph. Scanning elec-
tron photomicrographs demonstrate surface folds and the
focal loss of endothelial cells on mitral valve leaflets ob-
tained from patients with severe FMV/MVP and significant
mitral valvular regurgitation (18, Fig. 2). These surface
abnormalities may predispose an individual to infective
endocarditis and/or thromboembolic phenomena.
4. Diagnostic Considerations
It is clear that FMV should be the basis for the diagnosis of
MVP.1e3,25 Auscultatory findings and imaging characteristics
are directly related to the underlying pathology (Fig. 3).
The prevalence of clinically significant FMV/MVP in adults is
2 to 3%; the incidence and severity of abnormalities in FMV/
MVP increases with age.20,26e30 A family history is important
because FMV/MVP may be inherited, and it also may be
associated with heritable connective tissue disorders (e.g.,
Marfan syndrome).
Figure 3 Floppy mitral valve (FMV) is indicated in the center. FMV is the central issue in floppy mitral valve/mitral valve prolapse
(FMV/MVP) and mitral valvular regurgitation. Imaging techniques (e.g., echo: echocardiogram, MRI: magnetic resonance imaging,
and angio: ventricular angiogram) provide detailed information related to the mitral valve apparatus, leaflet thickness, and
chordae tendineae. Hemodynamics (e.g., Doppler, cardiac catheterisation, and MRI) can demonstrate the mitral regurgitation
severity. Auscultation or phonocardiogram provide information on the murmur or click. A late systolic murmur with postural
changes is also indicated. Skeletal or other abnormalities, if present, should also be defined. ALZ anterior leaflet, PLZ posterior
leaflet, C Z systolic click, S1 Z first heart sound, S2 Z second heart sound (modified from ref 99).
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a narrow anteroposterior chest diameter, straight back,
pectus excavatum, and scoliosis, may be present in FMV/
MVP. Patients with FMV/MVP may have an arm span greater
than the body height, are often thinner than normal, and
their height to weight ratio exceeds normal con-
trols.3,25,31e34 The presence of a non-ejection apical systolic
click with or without late apical systolic murmur comprise
the auscultatory criteria for the diagnosis of FMV/
MVP.3e5,8,21 A high-pitched mid to late apical systolic
murmur of mitral regurgitation frequently preceded by a
click may also be present. When the posterior mitral valve
leaflet prolapses, themurmur may radiate to the left sternal
border; in contrast, when the anterior leaflet prolapses, the
murmurmay radiate to the axilla and/or spine. In the upright
posture, the systolic click moves toward the first heart
sound, and the murmur becomes longer and often louder. A
systolic murmur may be present only in the upright position.
The auscultatory changes that occur with posture in patients
with FMV/MVP are predominately related to changes in the
LV volume, myocardial contractility, and heart rate. With
the progression of disease and when mitral regurgitation
becomes significant, the click may disappear, and the
murmur may become holosystolic.3,21
2. Electrocardiogram and chest-x-ray. In the majority of
patients with FMV/MVP, the electrocardiogram is normal.
Non-specific ST and T wave changes, especially in theinferior leads, have been described; however, they are non-
specific to FMV/MVP. These changes often improve with
exercise and/or beta-blockade therapy. When LV hyper-
trophy/enlargement or left atrial enlargement are present
as a result of chronic mitral valvular regurgitation, these
abnormalities may be identified via electrocardiogram.1,2
Chest X-ray typically indicates normal heart and lungs;
the skeletal abnormalities previously described may also be
identified if present. Patients with significant mitral
regurgitation may have left atrial and LV enlargement and
different degrees of pulmonary venous congestion following
heart failure development. Calcification of the mitral
annulus may be present in elderly patients. Acute rupture
of the chordae tendineae, which produces severe acute
mitral regurgitation, may result in pulmonary edema with a
nearly normal cardiac silhouette.2,3
3. Echocardiography and Doppler echocardiography. To
date, echocardiography and Doppler echocardiography are
the most widely used and most useful methods for the
diagnosis and follow-up of patients with FMV/MVP.3,35e43
The structure and function of the entire mitral valve
apparatus (e.g., leaflet thickness, chordae tendinae length,
and annular diameter), and LV and left atrial structure and
function may be precisely defined via echocardiogram.
Doppler echocardiography provides important information
related to the presence and severity of mitral valvular
regurgitation and indirect information related to pulmonary
Figure 5 Cardiac magnetic resonance imaging (courtesy of
Subha Raman, MD, The Ohio State University, Columbus Ohio,
USA). Note the thickness of the mitral valve leaflets (short
arrows on left panel) and the third chamber (arrow on right
panel). Ao Z aorta, AL Z anterior leaflet, LA Z left atrium,
LV Z left ventricle, RV Z right ventricle, PL Z posterior
leaflet, PM Z papillary muscle.
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MVP is typically defined as leaflet(s) displacement at least
2 mm above the mitral annulus in the parasternal long-axis
view. However, the diagnosis of FMV/MVP should be based
on firm criteria regarding structural changes and not only on
the presence of prolapse, which may represent a non-
specific finding. Leaflet thicknesses greater than 5 mm
are considered abnormal.26,36,37 The introduction of three-
dimensional echocardiography in clinical practice provides
more accurate information regarding the mitral valve
structure and function, and enables the precise definition
and measurement of the volume in the third chamber
(subsequently described; Fig. 4).39,40 During the early
stages of the disease, distinguishing a normal mitral valve
from a FMV with minor abnormalities may be difficult. In
some cases, repeat examination over several years may be
necessary to define FMV/MVP because of the progressive
nature of the disease.2,3
4. Cardiac magnetic resonance imaging (MRI). Cardiac
MRI may be used in clinical practice for the diagnosis of FMV/
MVPand especially for follow-up. CardiacMRI is currently the
most accurate method used to follow changes in the LV size,
function and mass, determine the left atrial size and func-
tion, and define the severity of mitral valvular regurgitation.
The thickness of the mitral valve leaflets and the third
chambermay also be defined using cardiac MRI3,41,44 (Fig. 5).
5. Cardiac catheterisation. Today, cardiac catheter-
isation is predominately performed prior to surgical inter-
vention in order to define the coronary anatomy.
Performing ventriculography may determine the severity of
mitral regurgitation and define LV and left atrial volumes
and function. Furthermore, intra-cardiac and pulmonary
artery pressure measurements provide important informa-
tion in certain cases. In addition, the characteristic
appearance of the mitral valve apparatus and the thickness
of mitral valve leaflets may be defined3,18,21 (Fig. 6).
6. Surgical inspection. The inspection of the mitral valve
at the time of surgery has contributed to a better definition
of the etiology of the disease and has provided a basis for
in vivo correlates with imaging techniques.3,26Figure 4 Three-dimensional echocardiography (courtesy of Vlasis
normal mitral valve (left) and a floppy mitral valve (right); third
Ao Z aorta, P Z posterior, PM Z posterior papillary muscle.7. Post-mortem examination. The characteristic
macroscopic appearance of FMV may easily be recognised.
A dynamic post-mortem examination with inspection of the
mitral valve from the left atrium prior to opening the LV and
observation of the mitral valve dynamics following LV filling
with fluid allows the identification of cusp prolapse. These
studies have provided important post-mortem observations
that parallel imaging techniques and surgical inspection.
After LV opening, the mitral valve leaflet area and chordae
tendineae length or rupture may be identified.19,20
5. Effects on Circulation
The pathophysiological consequences of the mitral valve
apparatus in patients with FMV/MVP may affect the entire
circulation. These effects of FMV/MVP on the circulation
will be briefly described.45Ninios, MD, St Lucas Hospital, Thessaloniki, Greece) indicates a
chamber is also shown. A Z anterior, AL Z anterior leaflet,
Figure 6 Upper panel: Ventriculogram in a patient with
floppy mitral valve/mitral valve prolapse (FMV/MVP) without
mitral regurgitation; arrows indicate posterior mitral leaflet
(PL) prolapse. Lower panel: Ventriculogram in a patient with
FMV/MVP and severe mitral regurgitation during systole; note
the large left atrium (LA) and the thickness of the mitral valve
(MV) leaflets (arrows). Ao Z aorta, LV Z left ventricle (from
ref 2).
78 K.D. Boudoulas et al.1. Third chamber. When prolapsing into the left atrium,
the FMV occupies part of the left atrial cavity that develops
a new chamber between the mitral annulus and the pro-
lapsing mitral valve leaflets during LV systole (Fig. 7). Thus,
during LV systole, even without mitral regurgitation, a
specific amount of blood occupies the space between the
mitral annulus and the mitral leaflets (i.e., the third
chamber).3,45 In severe FMV/MVP, the amount of blood
within the third chamber may represent a substantial
amount of the total potential LV stroke volume, which re-
sults in a significant decrease in the effective stroke vol-
ume. The degree of MVP increases in the upright posture,
which will result in an increase in the third chamber size
and may contribute to a further decrease in the effective
stroke volume and forward cardiac output.3,21,45 Thesealterations may explain the fatigue and exercise intoler-
ance in specific patients with FMV/MVP. Previous studies
from our laboratory have demonstrated an inability of pa-
tients with FMV/MVP to maintain the LV diastolic volume
and cardiac output during upright exercise (Fig. 7).3,46
2. Papillary muscle traction-stretch receptor activation.
In normal subjects, the distance between the papillary
muscle tips and the mitral annulus during LV systole re-
mains relatively constant. In contrast, in patients with
FMV/MVP, mitral valve leaflet displacement into the left
atrium results in papillary muscle displacement and an in-
crease in traction on the papillary muscle3,26 (Fig. 8).
Normal LV function is dependent on the integrity of papil-
lary muscle and chordae tendineae function; thus, these
changes may result in disorders of contractile patterns of
the LV. Furthermore, stretch receptors are activated as a
result of papillary muscle traction; stretch receptor acti-
vation may result in LV and papillary muscle membrane
depolarization and ventricular arrhythmias.47e50
3. Mitral valve-brain interactions. Human cardiac valves
have distinct patterns of innervation. The presence of these
nerve terminals suggests a neural basis for interactions
between the central nervous system and the mitral valve
(Fig. 8). The sub-endocardial surface on the atrial aspect at
the middle portion of the mitral valve is rich in nerve
endings, including afferent nerves. Mechanical stimuli from
this area caused by abnormal coaptation in patients with
FMV/MVP may cause abnormalities in autonomic nerve
feedback between the central nervous system and the
nerve endings of the mitral valve.3,45,47
4. Left atrial-LV structure/function and pulmonary cir-
culation. In patients with FMV/MVP, the mitral valve ab-
normalities progress over time and mild mitral valvular
regurgitation may become severe. The progression of mitral
valvular regurgitation is typically gradual, which permits
adaptive compensatory mechanisms. During LV systole in
patients with mitral regurgitation, part of the LV stroke
volume is ejected into the low pressure left atrium. The
left atrium gradually dilates and accommodates the extra
load. Chronic left atrial dilatation results in an increase in
left atrial compliance with relatively normal left atrial
pressure despite a substantial left atrial volume. The LV
volume also gradually increases because, in addition to the
blood flow from the pulmonary veins, blood ejected into
the left atrium during LV systole returns to the LV during
diastole. Thus, in patients with mitral regurgitation, sig-
nificant left atrial and LV dilatation and dysfunction may
occur.2,3 LV dilatation may cause papillary muscle
displacement, which further exacerbates mitral regurgita-
tion and results in a vicious cycle.51 In specific cases, the
left atrium may be affected more than the LV, and atrial
fibrillation may often occur. Atrial fibrillation may also in-
crease the severity of mitral regurgitation that improves
following restoration of sinus rhythm.52 Thus, the left atrial
and LV structure and function, as well as the cardiac
rhythm are important determinates of the natural history in
patients with FMV/MVP and mitral regurgitation. Further-
more, transmission of the left atrial pressure into the pul-
monary veins and pulmonary arterial capillaries may lead to
pulmonary arterial hypertension, which also comprises a
poor prognostic indicator. Factors that accelerate the nat-
ural course of mitral valvular regurgitation include chordae
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Figure 7 Left panel: Third chamber, which comprises the space between the mitral valve annulus and the prolapsing mitral valve
leaflets, in floppy mitral valve/mitral valve prolapse (FMV/MVP) is schematically presented; note that the size of the third chamber
increases in the upright position (modified from ref 2). Right panel: Cardiac index (CI) in patients with FMV/MVP syndrome was
lower in the upright compared with supine position, whereas in normal subjects, the CI was similar in the supine and upright
positions. The lower CI was related to a smaller left ventricular volume because the left ventricular ejection fraction was similar in
the supine and upright positions during exercise. Kilopond-meters per minute (kpm/min) (modified from ref 46).
Figure 8 Floppy mitral valve/mitral valve prolapse (FMV/MVP) is indicated in the center (modified from ref 27); the prolapsing
mitral valve becomes a space-occupying chamber in the left atrium (LA). FMV/MVP innervation is schematically demonstrated;
upper right panel indicates papillary muscle traction during left ventricular (LV) systole; lower right panel indicates a schematic
stretch activated receptor; left upper panel indicates interactions between the brain, heart, kidneys and adrenals; lower left panel
indicates a schematic beta-adrenergic receptor; lower panel indicates orthostatic phenomena (modified from ref. 47).
Floppy Mitral Valve/Mitral Valve Prolapse 79tendineae rupture, infective endocarditis, stiffening of the
aorta, and arterial hypertension.53e60
5. Aortic function. Evidence suggests that specific pa-
tients with FMV/MVP may have abnormal elastic properties
of the aorta. The aorta also stiffens with age. Stiffening ofthe aorta that results in systolic hypertension provides
resistance to LV ejection and increases the degree of mitral
regurgitation. These factors may accelerate the progression
of mitral regurgitation after the age of 50, when the aorta
typically becomes stiff.2,3,12
80 K.D. Boudoulas et al.6. FMV/MVP and Mitral Valvular Regurgitation:
Symptoms, Natural History, Complications
Related to Mitral Valve Abnormalities, and
Management
The symptoms and serious complications related to mitral
valve dysfunction in patients with FMV/MVP include pro-
gressive mitral valvular regurgitation, which may lead to
congestive heart failure, rupture of the chordae tendineae,
infective endocarditis, cardiac arrhythmias, and thrombo-
embolic phenomena. As a general rule, complications in-
crease with age (Fig. 9).
1. Symptoms related to mitral valvular regurgitation.
Significant symptoms related to mitral regurgitation typi-
cally develop at 50 to 60 years of age or later. Progressive
mitral regurgitation is related to various combinations of
annular dilatation, elongation or rupture of the chordae
tendineae, and ventricular dilatation. In some cases,
chordae tendineae rupture may lead to acute mitral
regurgitation. Patients with thick mitral valve leaflets,
mitral systolic murmur, men, and an age greater than 50
years are at increased risk for the development of signifi-
cant mitral regurgitation.2,3,18,25,37,53 When FMV/MVP is
part of a recognised heritable connective tissue disorder,
the natural history may primarily be related to the under-
lying disease rather than the FMV/MVP.9e11
2. Infective endocarditis is a complication of FMV/MVP.
Antibiotic prophylaxis for infective endocarditis is currently
a matter of considerable debate, as well as a subject of
changing attitudes and recommendations. Patients should
be encouraged to maintain the best possible oral hygiene to
reduce potential sources of bacterial seeding. The current
guidelines do not recommend prophylaxis for endocarditis
in patients with FMV/MVP; however, it should be noted that
an abnormal area of valve leaflets and not the mitral
regurgitation per se is responsible for endocarditis (Fig. 2).
It should also be highlighted that, in general, the incidence• Infective endocarditis
• Cardiac arrhythmias
• Sudden cardiac death
• Thromboembolic complications
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Figure 9 Floppy mitral valve/mitral valve prolapse/mitral
valvular regurgitation (FMV/MVP/MVR). Symptoms and compli-
cations related to FMV/MVP with MVR are plotted against age in
years. Increased symptoms related to MVR typically occur after
the age of 50 years. Left ventricular (LV) and left atrial (LA)
structural and functional abnormalities, atrial fibrillation and
heart failure (HF) may occur. Thromboembolic complications,
infective endocarditis and cardiac arrhythmias have been re-
ported in a wide range of ages (modified from ref. 2).of infective endocarditis has mildly increased following the
introduction of the most recent guidelines in which anti-
biotic prophylaxis is not recommended.61e63
3. Thromboembolic complications are another contro-
versial issue. Patients who exhibit clinical manifestations of
cerebral, retinal, or peripheral emboli should discontinue
oral contraceptives, abstain from tobacco smoking, and
undergo a careful cardiovascular and haematological eval-
uation prior to the consideration of long-term anti-
coagulation or antiplatelet therapy. In the case of atrial
fibrillation, the same approach should be used as in pa-
tients without FMV/MVP.3,64,65
4. Cardiac arrhythmias and sudden cardiac death. Car-
diac arrhythmias appear to be more frequent in patients
with FMV/MVP compared with the general population.66e68
The same diagnostic and therapeutic approach should be
used as in patients without FMV/MVP. Sudden cardiac death
in patients with FMV/MVP in the absence of significant
mitral regurgitation may occur; however, it is extremely
rare. Autopsy studies in patients with FMV/MVP who died
suddenly have demonstrated that the mitral leaflet length
and posterior leaflet thickness were increased in the hearts
from patients who had sudden cardiac death compared
with patients with FMV/MVP who died from other causes.
Patients with FMV/MVP who died suddenly without signifi-
cant mitral regurgitation tend to be relatively young
women.69e71 Ventricular fibrillation was the cause of car-
diac arrest in patients with FMV/MVP who had successful
cardiac resuscitation. Beta-blockade therapy may be
beneficial in patients with FMV/MVP who were successfully
resuscitated from cardiac arrest. Prophylactic use of an
implantable cardioverter defibrillator for secondary pre-
vention is recommended in these patients.69
5. Medical management of mitral regurgitation in FMV/
MVP. To date, there are limited data regarding the use of
pharmacologic agents to delay the progression of mitral
regurgitation. One study that comprised a small number of
patients suggested that therapy with Toprol XL, a beta-1
adrenergic receptor blocker, improved LV function in pa-
tients with isolated mitral regurgitation.72 The usefulness
of this therapy in clinical practice remains to be defined.
Furthermore, the attenuation of transforming growth fac-
tor beta with angiotensin II receptor blockers may prove to
be effective in the modulation of FMV/MVP progression. As
previously discussed, stiffening of the aorta with age may
increase the degree of mitral regurgitation and precipitate
the natural history of the disease.73 Better control of sys-
tolic hypertension, which is associated with a stiff aorta,
especially with drugs that improve aortic function, such as
angiotensin-converting enzyme inhibitors or calcium chan-
nel blockers, may prove effective in slowing the disease
progression; however, this concept remains to be defined.45
Thus, when significant mitral regurgitation is present in a
symptomatic patient with FMV/MVP or new onset of atrial
fibrillation, surgical intervention is recommended.2,3
Interventional therapy in patients with FMV/MVP and
mitral regurgitation
a. Surgical management. When severe mitral regurgita-
tion is present in a symptomatic patient with FMV/MVP,
especially when the LV ejection fraction (LVEF) is > 30%,
surgical intervention is recommended. If mitral valve repair
Floppy Mitral Valve/Mitral Valve Prolapse 81is highly likely, which is the treatment of choice, then
surgery is recommend in symptomatic patients with severe
mitral regurgitation as a result of FMV/MVP even if the LVEF
is < 30%. Mitral repair is also indicated in asymptomatic
patients with FMV/MVP and severe mitral regurgitation with
an LVEF > 60% and LV end systolic diameter < 40 mm or a
new onset of atrial fibrillation or pulmonary hypertension,
particularly if the likelihood of mitral valve repair is high. If
the likelihood of mitral repair in these asymptomatic pa-
tients is not high, then frequent follow-up (e.g., every 6
months) is a reasonable approach. An exercise tolerance
test may be useful to determine whether patients are truly
asymptomatic or if they develop pulmonary hypertension
(systolic >60 mm Hg), which is also an indication for sur-
gery. Furthermore, mitral valve surgery is indicated in
asymptomatic patients with FMV/MVP and severe mitral
regurgitation when the LVEF is between 30% to  60% or the
LV end systolic diameter is  40 mm. However, it should be
noted that LVEF may be underestimated in patients with
mitral regurgitation. The left atrial volume and function
may also facilitate a better definition of the timing for
surgical intervention. Mitral repair is preferable compared
with replacement for the treatment of mitral regurgitation
as a result of FMV/MVP because it better preserves LV
function compared with mitral valve replacement.
Furthermore, inherent adverse effects related to prosthetic
valves (e.g., anticoagulation therapy, risk of endocarditis or
thrombosis, noise of the mechanical prosthesis, or struc-
tural valve deterioration) may be avoided. In the previous
several years, the use of artificial chords has further
expanded the number of patients with FMV/MVP who may
effectively undergo mitral valve repair. This is especially
true for bileaflet and anterior leaflet prolapse.3,74e82 In the
previous few years at St. Luke’s Hospital, Thessaloniki,
Greece, a new, tailor-made, inexpensive annuloplasty de-
vice has been used that preserves annular valve function.
Furthermore, it helps to eliminate the development of
systolic anterior motion (SAM) of the mitral valve, which
comprises one complication associated with mitral valve
repair that it is difficult to manage (Fig. 10). This technique
has been used in more than two hundred patients to dateFigure 10 Tailor-made mitral annuloplasty band used at St
Luke’s Hospital is shown. Surgical implantation of the mitral
annuloplasty band is also shown (left image).(bileaflet and anterior repairs included) with excellent re-
sults and without an incidence of SAM. The custom-made
annuloplasty band is composed of dacron and titanium
clips.
b. Transcatheter interventions of mitral regurgitation
in FMV/MVP. In patients who are at a prohibitive risk for
surgery, transcatheter mitral valve repair using the mitra-
clip device can be used. Furthermore, transcatheter mitral
valve replacement may be an option in the near future as
clinical trials are underway.83e867. Acute Mitral Regurgitation
The most common causes of acute mitral regurgitation are
chordae tendineae rupture, papillary muscle rupture and
infective endocarditis. Distinguishing the three most com-
mon types of acute mitral regurgitation based on clinical
evaluation is relatively easy. Rupture of the chordae ten-
dineae is the most common cause of acute mitral regurgi-
tation in patients with FMV/MVP. In severe acute mitral
regurgitation, a substantial volume of blood is ejected into
the low pressure left atrium during LV systole. There is
insufficient time to enable left atrial and LV dilatation;
thus, the amount of the regurgitant volume will result in a
substantial increase in the left atrial pressure. Left atrial v-
waves > 60 mmHg are not uncommon. The marked increase
in the pulmonary venous pressure may result in pulmonary
edema. Since the LV is of normal size and a large amount of
blood goes into the left atrium during LV systole, the for-
ward stroke volume is markedly diminished. In addition to
pulmonary oedema, the net result is tissue hypoperfusion
and shock. The systolic murmur typically peaks in mid-
systole and diminishes in intensity prior to the second heart
sound in contrast to chronic mitral regurgitation where the
murmur is holosystolic. The sudden appearance of a new
systolic murmur associated with dyspnea, tissue hypo-
perfusion and shock should raise the suspicion of acute
mitral regurgitation. In cases of FMV/MVP with a previously
identified systolic murmur, patients present with an alter-
ation in the quality of the murmur, tissue hypoperfusion
and/or dyspnoea. In severe acute mitral regurgitation, an
emergent surgical intervention is indicated. Patients with
less severe mitral regurgitation may gradually progress and
may respond to medical management without surgery at
least during the acute phase. However, most patients with
chordae tendineae rupture will require mitral valve surgery
in 6 to 12 months following the rupture.2,3,198. FMV/MVP Syndrome
Certain patients with FMV/MVP may have symptoms that
cannot be explained based on the severity of mitral
regurgitation alone. Neuroendocrine or autonomic nervous
system functional abnormalities have been postulated as an
explanation for the symptoms in this patient group, which is
currently classified as the FMV/MVP syndrome.2,3,25
1. Symptoms related to FMV/MVP syndrome. The most
common symptoms in these patients include palpitations,
orthostatic phenomena (tachycardia, hypotension), cardiac
arrhythmias, syncope or pre-syncope, exercise intolerance/
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Figure 11 Left panel: Dynamic spectrum, time in years, and
progression of floppy mitral valve/mitral valve prolapse (FMV/
MVP) are indicated. A subtle gradation exists between the
normal mitral valve and valves with mild FMV/MVP without
mitral valvular regurgitation (MVR). Progression from FMV/MVP
withoutMVR toFMV/MVPwithMVRmayoccur. Right panel: Large
circle represents the total number of patients with FMV/MVP.
Patients with FMV/MVP may be symptomatic or asymptomatic.
Symptoms may be directly related to mitral regurgitation (dark
grey circle) or FMV/MVP syndrome (light grey circle). Patients
with symptoms related to mitral regurgitation may also have
symptoms related to FMV/MVP syndrome. In the individual pa-
tient analysis, anatomical and pathophysiological abnormalities
for each individual patient at each stage should be defined, and
therapy should be based on these findings (modified from ref. 1).
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tom onset is approximately 30 years of age with a wide
range of symptom onset. The symptoms of FMV/MVP syn-
drome have been previously reported from numerous
investigators.87e96 In most of these studies, however,
symptoms were reported at one particular time during the
natural course of the disease and thus, the duration of
symptoms was not precisely defined. Furthermore, in the
majority of these studies, the diagnosis of MVP was based
on “soft” echocardiographic criteria (M-mode or two
dimensional) without defining whether the mitral valve was
floppy. In a recent study from our laboratory, the symptoms
related to FMV/MVP syndrome were analysed in 98 patients
from the time of onset until reconstructive surgery was
performed.26,97 The median age of symptom onset was 30
years (range 10 to 63 years) and the median duration of
symptoms from onset to mitral valve surgery was 16 years
(range 3 to 50 years). Thus, it is unlikely that these symp-
toms were related to the severity of mitral regurgitation.
The diagnosis of FMV in our study was established with
transoesophageal two- and three- dimensional echocardi-
ography, and it was also confirmed with direct inspection of
the mitral valve in the operating room in all patients. Pa-
tients had diffuse (n Z 40) or regional (n Z 58) thickening
of the mitral valve leaflets. Leaflet thickening was often
associated with an elongated chordae tendineae, chordae
tendineae rupture, flail mitral leaflet, and mitral annular
dilatation. The incidence of symptoms related to FMV/MVP
syndrome in the entire group was 42%. The incidence of
symptoms consistent with FMV/MVP syndrome was
increased in the patients with diffuse thickening of the
mitral valve leaflets (52.5 %) compared with the patients
with regional thickening of the mitral valve leaflets (31%).
Palpitations were persistent in most patients, whereas
other symptoms, such as fatigue, dyspnea and chest pain,
disappeared after surgery. The cause of the palpitations
was not precisely defined. It was not clear whether the
patients were aware of a “fast heart beat” or had prema-
ture atrial or ventricular contractions. It is also possible
that the patients were more sensitive in recognising pre-
mature beats or changes in heart rate compared with the
general population. Atrial fibrillation was not responsible
for symptoms in patients with palpitations. It can be
concluded therefore, that patients with FMV/MVP may have
symptoms consistent with the FMV/MVP syndrome for many
years prior to the development of significant mitral regur-
gitation and thus, cannot be attributed to mitral regurgi-
tation per se. These symptoms were more prominent in
women compared to men.25
2. Pathogenesis of symptoms in FMV/MVP syndrome.
Symptoms in women with FMV/MVP syndrome may be
related, in part, to beta-adrenergic receptor poly-
morphisms that increase the sensitivity to adrenergic
stimulation.25 In addition to a high adrenergic tone, there
are several other mechanisms that may be related to the
pathogenesis of symptoms in patients with FMV/MVP syn-
drome.87e96 These mechanisms include the development of
the third chamber, which may result in a low stroke vol-
ume, particularly in the upright position45,46; papillary
muscle traction, which may produce chest pain that results
in the activation of stretch receptors that lead to mem-
brane depolarisation and cardiac arrhythmias; and mitralvalve nerve ending stimulation, which may cause an
abnormal autonomic nerve feedback between the central
nervous system and the mitral valve3,47e50 (Fig. 8).
3. Management of patients with FMV/MVP syndrome.
Careful explanation to patients of the findings and potential
mechanisms of symptoms will provide a foundation for long-
term management. Importantly, patients with FMV/MVP
syndrome should be protected from unnecessary surgery if
theydonot exhibit severemitral regurgitation. Theprognosis
regarding life expectancy appears to be very good. In some
cases, patients with FMV/MVP syndrome may be sensitive to
volume depletion and should be advised to avoid or discon-
tinue chronic diuretic therapy if not absolutely indicated.
Fluid intake before, during and after exercise may be bene-
ficial, especially in patients with a low intravascular volume.
Catecholamine and cycle AMP stimulants, such as caffeine,
cigarettes, alcohol and over-the-counter medications that
contain epinephrine, should be avoided. Low doses of beta-
blockers during a short period of time, especially if the pa-
tient is sensitive to adrenergic stimulation during stressful
periods, may be beneficial. Studies suggest that aerobic ex-
ercise may provide good results in specific patients. At pre-
sent, there is insufficient information for the use of the
bradycardic drug procoralan in cases of orthostatic tachy-
cardia in patients with FMV/MVP syndrome.2,3
9. Individual Patient Analysis
FMV/MVP includes a heterogeneous group of patients with
a broad spectrum of mitral valve abnormalities that range
from mild to severe. Thus, in each case, it is important to
Floppy Mitral Valve/Mitral Valve Prolapse 83not only establish the diagnosis of FMV/MVP, but also
define the abnormalities and their severities. Symptoms in
patients with FMV/MVP may be directly related to the
underlying mitral valve pathology, as well as progressive
mitral regurgitation and its complications. However, in
some cases of FMV/MVP, the symptoms cannot be
explained based only on the severity of mitral regurgita-
tion alone (Fig. 11). Activation of the autonomic nervous
system or neuroendocrine dysfunction has been implicated
in the explanation of symptoms in this group of patients
that at present it is referred as the FMV/MVP syn-
drome.3,25 Symptoms in patients with FMV/MVP syndrome
may coexist with symptoms related to significant mitral
regurgitation and, in certain instances, may persist
following mitral valve surgery. The individual patient
analysis represents a logical approach to the diagnosis and
risk stratification of each patient in this heterogeneous
group.2,18,98 Anatomical and pathophysiological abnormal-
ities for each individual patient should be defined, and
therapy should be based on these findings.References
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